Skip to main content
Premium Trial:

Request an Annual Quote

Texas Genomic Medicine Group Joins International Knockout Mouse Initiative

NEW YORK (GenomeWeb News) - The Texas Institute for Genomic Medicine, a Houston-based non-profit institution, today said it has joined the International Knockout Mouse Consortium, a global initiative that provides resources for researchers using genetically engineered mice.
 
The IKMC includes the National Institutes of Health’s Knockout Mouse Project, which was launched last year, as well as Canada’s North American Conditional Mouse Mutagenesis Project and the EU-funded European Conditional Mouse Mutagenesis Program.
 
TIGM said it has a catalog of more than 200,000 C57BL/6N strain embryonic stem cell clones, representing more than 8,600 genes that have been inactivated. It expects to have more than 350,000 clones with mutations in around 13,000 genes by the end of the year.
 
The institute said it has also “contracted access” to a second library of 272,000 genetically modified ES cell clones in the 129SvEv mouse strain.
 
Richard Finnell, TIGM president, said in a statement that the institute will begin to deposit gene trap tag sequence data in GenBank “on or about June 1."
 
TIGM said that because mice have 99 percent of their genes in common with humans, and 85 percent genetic similarity across 22,000 to 24,000 genes, they are “ideal for scientific and medical understanding of the role a specific gene plays in the cell's development, function and health.”

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.